Adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients on HD with HCV infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of participants with relapse‐free survival at ≥ 12 months · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Change in disability Assessed by: EDSS · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
1 finding from 1 review
New or enlarging T2‐hyperintense lesions · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
The review found no eligible studies for this question.
1 finding from 1 review
Leaving the study early · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower dropouts compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Sustained disease progression‐free survival · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with relapsing–remitting multiple sclerosis
Alemtuzumab 12 mg showed no clear difference in adverse events, including serious events Assessed by: number of… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Change in disability Assessed by: EDSS · adults with relapsing–remitting multiple sclerosis
1 finding from 1 review
Number of participants with new or enlarging T2‐hyperintense lesions on MRI · adults with relapsing–remitting multiple sclerosis
The review found no eligible studies for this question.
1 finding from 1 review
Dropout · adults with relapsing–remitting multiple sclerosis
It is very uncertain whether alemtuzumab 12 mg changes dropouts Assessed by: number of participants who dropped out compared with interferon beta‐1a (very low certainty).
1 finding from 1 review
Proportion of participants with relapse‐free survival at ≥ 12 months · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower relapse‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Sustained disease progression‐free survival · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg may leads to lower sustained disease progression‐free survival compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Adverse events, including serious adverse events Assessed by: number of participants with ≥ 1 event · adults with multiple sclerosis Interventions: immunosuppressive and immunomodulatory drugs Comparator: placebo Outcome: withdrawals due to…
Alemtuzumab 24 mg showed no clear difference in adverse events, including serious adverse events Assessed by: number… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Relapse · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab probably leads to lower number of participants experiencing ≥ 1 relapse compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants experiencing disability progression · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing disability progression compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with any adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any adverse events compared with interferon beta‐1a (moderate certainty).
1 finding from 1 review
Number of participants with any serious adverse events · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab showed no clear difference in number of participants with any serious adverse events compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with adverse events leading to study discontinuation · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants experiencing treatment discontinuation caused… compared with interferon beta‐1a (low certainty).
1 finding from 1 review
Number of participants with gadolinium‐enhancing T1 lesions on MRI · patients with relapsing‐remitting multiple sclerosis
Ocrelizumab may leads to lower number of participants with gadolinium‐enhancing T1 lesions on MRI compared with interferon beta‐1a (low certainty).
1 finding from 1 review